| Identification | Back Directory | [Name]
13,14-dihydro-15-keto-tetranor Prostaglandin D2 | [CAS]
1204116-69-7 | [Synonyms]
CIXGXJHOQWHINC-NFAWXSAZSA-N
13,14-dihydro-15-keto-tetranor Prostaglandin D2
13,14-dihydro-15-keto-tetranor Prostaglandin D2 Exclusive | [Molecular Formula]
C16H26O5 | [MOL File]
1204116-69-7.mol | [Molecular Weight]
298.37 |
| Chemical Properties | Back Directory | [Boiling point ]
497.7±30.0 °C(Predicted) | [density ]
1.127±0.06 g/cm3(Predicted) | [solubility ]
DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml | [pka]
4.68±0.10(Predicted) |
| Hazard Information | Back Directory | [Description]
A common metabolic pathway for several prostaglandins (PGs), including PGD2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor-PGDM. 13,14-dihydro-15-keto-tetranor PGD2 is a potential metabolite of PGD2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGD2 , which is a known agonist for the CRTH2/DP2 receptor. | [Uses]
13,14-Dihydro-15-keto-tetranor prostaglandin D2 (Compound VI) is a prostaglandin D2 metabolite. 13,14-Dihydro-15-keto-tetranor prostaglandin D2 as a biomarker can be used to study prostaglandin D2-related diseases[1]. | [Definition]
ChEBI: 13,14-dihydro-15-keto-tetranor Prostaglandin D2 is a member of cyclopentanols. | [References]
[1] Nanbu F, et al. Biomarker for prostaglandin d2-related disease treatment and measurement method of the same. JP2010002416A. 2010-01-07. |
|
|